

NEOPROBE TO PRESENT AT BIO CEO CONFERENCE

DUBLIN, OHIO – February 3, 2009 -- Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that its President and Chief Executive Officer, David Bupp, will present on Monday, February 9, 2009 at 2:15PM EST, during the 11th Annual BIO CEO & Investor Conference to be held at the Waldorf Astoria Hotel in New York, NY.

Mr. Bupp will provide a corporate overview, including an update and discussion of the clinical development program for Lymphoseek[®], Neoprobe's lead drug product. Interested parties can access a live, or archived, internet broadcast of the presentation at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NEOP&item_id=2087972.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe[®] GDS line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix[®] line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek[®] and RIGScan[®] CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com.